Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb5871 in Patients with IgG4-Related Disease (INDIGO)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb5871 in Patients with IgG4-Related Disease (INDIGO)

Planning
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Obexelimab (Primary)
  • Indications Immunological disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms INDIGO
  • Sponsors Xencor
  • Most Recent Events

    • 05 Nov 2018 According to a Xencor media release, company plans to initiate this trial by Early 2019.
    • 05 Oct 2018 According to a Xencor media release, this study is expected to start by year end.
    • 27 Feb 2018 According to a Xencor media release, Engagement with the European Medicines Agency to discuss a path forward for Phase 3 development in IgG4-RD expected in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top